Correction: Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier (Molecular Pharmaceutics (2014) 11: 11 (4164-4178) DOI: 10.1021/mp500389v);Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier

Molecular Pharmaceutics

Volumn 11, Issue 11, 2015, Pages 4164-4178

  Lu, Jianqin ^a,b   Zhao, Wenchen ^a   Huang, Yixian ^a,b   Liu, Hao ^c   Marquez, Rebecca ^c   Gibbs, Robert B ^a   Li, Jiang ^a,b   Venkataramanan, Raman ^a   Xu, Liang ^c   Li, Shulin ^d   Li, Song ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

antitumor activity; doxorubicin; folic acid; multidrug resistance; nanomicelles; targeted delivery

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DOXORUBICIN; FOLIC ACID; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; DRUG CARRIER; EMBELIN; MACROGOL DERIVATIVE; MICELLE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BREAST NEOPLASMS; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HUMANS; MICE; MICE, INBRED BALB C; MICELLES; NANOPARTICLES; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84920788620     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.9b00818     Document Type: Erratum

References (53)

1. Takemura, G.; Fujiwara, H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 2007, 49, 330-352
2. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 2004, 56, 185-229
3. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986, 46, 6387-6392
4. Gao, Z.; Lukyanov, A. N.; Singhal, A.; Torchilin, V. P. Diacyllipid-Polymer Micelles as Nanocarriers for Poorly Soluble Anticancer Drugs Nano Lett. 2002, 2, 979-982
5. Li, S. D.; Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer Biochim. Biophys. Acta 2009, 1788, 2259-2266
6. Woodle, M. C.; Engbers, C. M.; Zalipsky, S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes Bioconjugate Chem. 1994, 5, 493-496
7. O'Brien, M. E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 2004, 15, 440-449
8. Al-Batran, S. E.; Meerpohl, H. G.; Von Minckwitz, G.; Atmaca, A.; Kleeberg, U.; Harbeck, N.; Lerbs, W.; Hecker, D.; Sehouli, J.; Knuth, A.; Jager, E. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer Oncology 2006, 70, 141-146
9. Lorusso, D.; Di Stefano, A.; Carone, V.; Fagotti, A.; Pisconti, S.; Scambia, G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ("hand-foot" syndrome) Ann. Oncol. 2007, 18, 1159-1164
10. Von Gruenigen, V.; Frasure, H.; Fusco, N.; DeBernardo, R.; Eldermire, E.; Eaton, S.; Waggoner, S. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients Cancer 2010, 116, 4735-4743
11. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao Functionalized micellar systems for cancer targeted drug delivery J. Pharm. Res. 2007, 24, 1029-1046
12. Huang, Y.; Lu, J.; Gao, X.; Li, J.; Zhao, W.; Sun, M.; Stolz, D. B.; Venkataramanan, R.; Rohan, L. C.; Li, S. PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel Bioconjugate Chem. 2012, 23, 1443-1451
13. Lu, J.; Huang, Y.; Zhao, W.; Marquez, R. T.; Meng, X.; Li, J.; Gao, X.; Venkataramanan, R.; Wang, Z.; Li, S. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers Biomaterials 2013, 34, 1591-1600
14. Lu, J.; Huang, Y.; Zhao, W.; Chen, Y.; Li, J.; Gao, X.; Venkataramanan, R.; Li, S. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel Mol. Pharmaceutics 2013, 10, 2880-2890
15. Zhang, X.; Lu, J.; Huang, Y.; Zhao, W.; Chen, Y.; Li, J.; Gao, X.; Venkataramanan, R.; Sun, M.; Stolz, D. B.; Zhang, L.; Li, S. PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel Bioconjugate Chem. 2013, 24, 464-472
16. Gao, X.; Huang, Y.; Makhov, A. M.; Epperly, M.; Lu, J.; Grab, S.; Zhang, P.; Rohan, L.; Xie, X. Q.; Wipf, P.; Greenberger, J.; Li, S. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers Mol. Pharmaceutics 2013, 10, 187-198
17. Luo, J.; Xiao, K.; Li, Y.; Lee, J. S.; Shi, L.; Tan, Y. H.; Xing, L.; Holland Cheng, R.; Liu, G. Y.; Lam, K. S. Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment Bioconjugate Chem. 2010, 21, 1216-1224
18. Li, Y.; Xiao, K.; Luo, J.; Lee, J.; Pan, S.; Lam, K. S. A novel size-tunable nanocarrier system for targeted anticancer drug delivery J. Controlled Release 2010, 144, 314-323
19. Bedi, D.; Gillespie, J. W.; Petrenko, V. A., Jr.; Ebner, A.; Leitner, M.; Hinterdorfer, P.; Petrenko, V. A. Targeted delivery of siRNA into breast cancer cells via phage fusion proteins Mol. Pharmaceutics 2013, 10, 551-559
20. Cheng, C.; Wei, H.; Zhu, J. L.; Chang, C.; Cheng, H.; Li, C.; Cheng, S. X.; Zhang, X. Z.; Zhuo, R. X. Functionalized thermoresponsive micelles self-assembled from biotin-PEG-b-P(NIPAAm-co-HMAAm)-b-PMMA for tumor cell target Bioconjugate Chem. 2008, 6, 1194-1201
21. Song, N.; Ding, M.; Pan, Z.; Li, J.; Zhou, L.; Tan, H.; Fu, Q. Construction of targeting-clickable and tumor-cleavable polyurethane nanomicelles for multifunctional intracellular drug delivery Biomacromolecules 2013, 14, 4407-4419
22. Wang, T.; Petrenko, V. A.; Torchilin, V. P. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity Mol. Pharmaceutics 2010, 7, 1007-1014
23. Lächelt, U.; Wittmann, V.; Müller, K.; Edinger, D.; Kos, P.; Höhn, M.; Wagner, E. Synthetic Polyglutamylation of Dual-Functional MTX Ligands for Enhanced Combined Cytotoxicity of Poly(I:C) Nanoplexes Mol. Pharm. 2014, 10.1021/mp500017u
24. Yan, L.; Chen, W.; Zhu, X.; Huang, L.; Wang, Z.; Zhu, G.; Roy, V. A.; Yu, K. N.; Chen, X. Folic acid conjugated self-assembled layered double hydroxide nanoparticles for high-efficacy-targeted drug delivery Chem. Commun. (Cambridge) 2013, 49, 10938-10940
25. Li, H.; Piao, L.; Yu, B.; Yung, B. C.; Zhang, W.; Wang, P. G.; Lee, J. L.; Lee, R. J. Delivery of calf thymus DNA to tumor by folate receptor targeted cationic liposomes. Delivery of calf thymus DNA to tumor by folate receptor targeted cationic liposomes Biomaterials 2011, 32, 6614-6620
26. van Dongen, M. A.; Silpe, J. E.; Dougherty, C. A.; Kanduluru, A. K.; Choi, S. K.; Orr, B. G.; Low, P. S.; Banaszak Holl, M. M. Avidity mechanism of dendrimer-folic Acid conjugates Mol. Pharmaceutics 2014, 11, 1696-1706
27. Danquah, M.; Li, F.; Duke, C. B.; Miller, D. D.; Mahato, R. I. Micellar delivery of bicalutamide and embelin for treating prostate cancer Pharm. Res. 2009, 26, 2081-2092
28. Sreepriya, M.; Bali, G. Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats Fitoterapia 2005, 76, 549-555
29. Dai, Y.; Qiao, L.; Chan, K. W.; Yang, M.; Ye, J.; Ma, J.; Zou, B.; Gu, Q.; Wang, J.; Pang, R.; Lan, H. Y.; Wong, B. C. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis Cancer Res. 2009, 69, 4776-4783
30. Heo, J. Y.; Kim, H. J.; Kim, S. M.; Park, K. R.; Park, S. Y.; Kim, S. W.; Nam, D.; Jang, H. J.; Lee, S. G.; Ahn, K. S.; Kim, S. H.; Shim, B. S.; Choi, S. H.; Ahn, K. S. Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN Cancer Lett. 2011, 308, 71-80
31. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R.; Fang, X.; Guo, R.; Zhang, M.; Lippman, M. E.; Yang, D.; Wang, S. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database J. Med. Chem. 2004, 47, 2430-2440
32. Li, F.; Danquah, M.; Mahato, R. I. Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery Biomacromolecules 2010, 11, 2610-2620
33. Zhang, Y.; Huang, Y.; Zhang, P.; Gao, X.; Gibbs, R. B.; Li, S. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells Int. J. Nanomedicine 2012, 7, 4473-4485
34. Paulos, C. M.; Reddy, J. A.; Leamon, C. P.; Turk, M. J.; Low, P. S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery Mol. Pharmacol. 2004, 66, 1406-1414
35. Wang, Y.; Wang, R.; Lu, X.; Lu, W.; Zhang, C.; Liang, W. Pegylated phospholipids-based self-assembly with water-soluble drugs Pharm. Res. 2010, 27, 361-370
36. Hu, C. M.; Zhang, L. Therapeutic nanoparticles to combat cancer drug resistance Curr. Drug Metab. 2009, 10, 836-841
37. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53, 615-627
38. Yuan, H.; Li, X.; Wu, J.; Li, J.; Qu, X.; Xu, W.; Tang, W. Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance Curr. Med. Chem. 2008, 15, 470-476
39. Chavanpatil, M. D.; Khdair, A.; Gerard, B.; Bachmeier, C.; Miller, D. W.; Shekhar, M. P.; Panyam, J. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux Mol. Pharmaceutics 2007, 4, 730-738
40. Collnot, E. M.; Baldes, C.; Wempe, M. F.; Kappl, R.; Hüttermann, J.; Hyatt, J. A.; Edgar, K. J.; Schaefer, U. F.; Lehr, C. M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity Mol. Pharmaceutics 2007, 4, 465-474
41. Sharma, A. K.; Zhang, L.; Li, S.; Kelly, D. L.; Alakhov, V. Y.; Batrakova, E. V.; Kabanov, A. V. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant J. Controlled Release 2008, 131, 220-227
42. Zhang, Z.; Liu, Z.; Ma, L.; Jiang, S.; Wang, Y.; Yu, H.; Yin, Q.; Cui, J.; Li, Y. Reversal of multidrug resistance by mitochondrial targeted self-assembled nanocarrier based on stearylamine Mol. Pharmaceutics 2013, 10, 2426-2434
43. Loo, T. W.; Bartlett, M. C.; Clarke, D. M. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein Mol. Pharmaceutics 2004, 1, 426-433
44. Desai, P. V.; Sawada, G. A.; Watson, I. A.; Raub, T. J. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux Mol. Pharmaceutics 2013, 10, 1249-1261
45. Ogawara, K.; Un, K.; Tanaka, K.; Higaki, K. T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells J. Controlled Release 2009, 133, 4-10
46. Klaassen, C. D.; Aleksunes, L. M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation Pharmacol. Rev. 2010, 62, 1-96
47. Dintaman, J. M.; Silverman, J. A. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm. Res. 1999, 16, 1550-1556
48. Xiao, K.; Luo, J.; Li, Y.; Lee, J. S.; Fung, G.; Lam, K. S. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma J. Controlled Release 2011, 155, 272-281
49. Chitra, M.; Sukumar, E.; Suja, V.; Devi, C. S. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product Chemotherapy 1994, 40, 109-113
50. Bhandari, U.; Jain, N.; Pillai, K. K. Further studies on antioxidant potential and protection of pancreatic beta-cells by Embelia ribes in experimental diabetes Exp. Diabetes Res. 2007, 2007, 15803-15808
51. Singh, D.; Singh, R.; Singh, P.; Gupta, R. S. Effects of embelin on lipid peroxidation and free radical scavenging activity against liver damage in rats Basic Clin. Pharmacol. Toxicol. 2009, 105, 243-248
52. Chen, J.; Corbin, I. R.; Li, H.; Cao, W.; Glickson, J. D.; Zheng, G. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo J. Am. Chem. Soc. 2007, 129, 5798-5799
53. Hou, L.; Yao, J.; Zhou, J.; Zhang, Q. Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system Biomaterials 2012, 33, 5431-5440